Mitros, Mark

Mitros, Mark was paid $552K by Medicaid between Oct 2020 and Oct 2023, across 9 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.

33Billing provider infoMITROS, MARK
WEXFORD, PA 15090

33aNPI1033111778assigned 08/12/2005

33bProvider typePhysical Medicine & Rehabilitation Physician

28Total paid$552K

24GClaims10,946

24DCodes billed9

24AFirst – last monthOct 2020 – Oct 2023

Compared with peers

Next to other Physical Medicine & Rehabilitation Physician providers in Pennsylvania

Rank by total paid#6 of 148

Median peer was paid$8K

This provider vs. median74×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	623	$29K
2021	4,611	$253K
2022	3,947	$188K
2023	1,765	$82K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	41%	6,396	6,272	$224K
95886		17%	1,580	851	$94K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	11%	905	902	$61K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.5%	492	491	$52K
95910		7.2%	347	347	$40K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	5.2%	367	367	$29K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	4.8%	416	396	$27K
95911		3.3%	140	140	$18K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.4%	303	299	$8K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.